Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 810

1.

Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy.

Wu M, Pokreisz P, Swinnen M, Caluwe E, Gillijns H, Vanden Driessche N, Casazza A, Verbeken E, Collen D, Janssens S.

J Cardiovasc Transl Res. 2017 Aug;10(4):348-358. doi: 10.1007/s12265-017-9742-4. Epub 2017 Apr 10.

PMID:
28397162
2.

Placental growth factor 2--A potential therapeutic strategy for chronic myocardial ischemia.

Wu M, Claus P, Vanden Driessche N, Reyns G, Pokreisz P, Gillijns H, Caluwe E, Bogaert J, Collen D, Janssens S.

Int J Cardiol. 2016 Jan 15;203:534-42. doi: 10.1016/j.ijcard.2015.10.177. Epub 2015 Oct 26.

PMID:
26569359
3.

In memoriam: Burton E. Sobel a tribute from family, friends and colleagues October 21, 1937 - May 3, 2013.

Schneider DJ, Avera ES, Bergmann SR, Braunwald E, Collen D, Frye R, Jaffe A, Kirk RJ, Ludbrook PA, Roberts R, Spector P, Vlasuk GP, Willerson JT.

Exp Biol Med (Maywood). 2013 Oct;238(10):1101-15. doi: 10.1177/1535370213505824. No abstract available.

PMID:
24072785
4.

Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Wallays G, Nuyens D, Silasi-Mansat R, Souffreau J, Callaerts-Vegh Z, Van Nuffelen A, Moons L, D'Hooge R, Lupu F, Carmeliet P, Collen D, Dewerchin M.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2881-8. doi: 10.1161/ATVBAHA.111.237859. Epub 2011 Sep 22.

PMID:
21940951
5.

Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction.

Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, Vandenwijngaert S, Dépelteau H, Streb W, Chaothawee L, Maes F, Gheysens O, Debyser Z, Gillijns H, Pellens M, Vandendriessche T, Chuah M, Collen D, Verbeken E, Belmans A, Van de Werf F, Bogaert J, Janssens S.

J Am Coll Cardiol. 2010 May 18;55(20):2232-43. doi: 10.1016/j.jacc.2009.10.081.

6.

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P.

Cell. 2010 Apr 2;141(1):178-90. doi: 10.1016/j.cell.2010.02.039.

7.

Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury.

Szelid Z, Pokreisz P, Liu X, Vermeersch P, Marsboom G, Gillijns H, Pellens M, Verbeken E, Van de Werf F, Collen D, Janssens SP.

Basic Res Cardiol. 2010 Mar;105(2):169-79. doi: 10.1007/s00395-009-0077-4. Epub 2009 Dec 18.

PMID:
20020305
8.

Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions.

Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K, Hansson GK, Carmeliet P.

Cardiovasc Res. 2010 Apr 1;86(1):29-36. doi: 10.1093/cvr/cvp380. Epub 2009 Dec 1.

PMID:
19952000
9.

The tissue-type plasminogen activator story.

Collen D, Lijnen HR.

Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1151-5. doi: 10.1161/ATVBAHA.108.179655.

PMID:
19605778
10.

Emerging treatments for thrombocytopenia: increasing platelet production.

Peeters K, Stassen JM, Collen D, Van Geet C, Freson K.

Drug Discov Today. 2008 Sep;13(17-18):798-806. doi: 10.1016/j.drudis.2008.06.002. Epub 2008 Jul 17. Review.

PMID:
18602017
11.

Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.

Marsboom G, Pokreisz P, Gheysens O, Vermeersch P, Gillijns H, Pellens M, Liu X, Collen D, Janssens S.

Stem Cells. 2008 Apr;26(4):1017-26. doi: 10.1634/stemcells.2007-0562. Epub 2008 Feb 7.

12.

Role of Gas6 in erythropoiesis and anemia in mice.

Angelillo-Scherrer A, Burnier L, Lambrechts D, Fish RJ, Tjwa M, Plaisance S, Sugamele R, DeMol M, Martinez-Soria E, Maxwell PH, Lemke G, Goff SP, Matsushima GK, Earp HS, Chanson M, Collen D, Izui S, Schapira M, Conway EM, Carmeliet P.

J Clin Invest. 2008 Feb;118(2):583-96. doi: 10.1172/JCI30375.

13.

Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.

Nagai N, Okada K, Kawao N, Ishida C, Ueshima S, Collen D, Matsuo O.

Neurosci Lett. 2008 Feb 13;432(1):46-9. doi: 10.1016/j.neulet.2007.12.004. Epub 2007 Dec 8.

PMID:
18164548
14.

Ttrap is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination.

Esguerra CV, Nelles L, Vermeire L, Ibrahimi A, Crawford AD, Derua R, Janssens E, Waelkens E, Carmeliet P, Collen D, Huylebroeck D.

Development. 2007 Dec;134(24):4381-93.

15.

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P.

Cell. 2007 Nov 2;131(3):463-75.

16.

Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.

Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, Pellens M, Gillijns H, Swinnen M, Graveline A, Collen D, Dewerchin M, Brouckaert P, Bloch KD, Janssens S.

Circulation. 2007 Aug 21;116(8):936-43. Epub 2007 Aug 6.

PMID:
17679618
17.

Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.

Lijnen HR, Van Hoef B, Kemp D, Collen D.

Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15.

PMID:
17616257
18.

Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.

Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR.

J Thromb Haemost. 2007 Aug;5(8):1732-9. Epub 2007 May 21.

19.

Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.

Zwerts F, Lupu F, De Vriese A, Pollefeyt S, Moons L, Altura RA, Jiang Y, Maxwell PH, Hill P, Oh H, Rieker C, Collen D, Conway SJ, Conway EM.

Blood. 2007 Jun 1;109(11):4742-52. Epub 2007 Feb 13.

20.

A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.

Verhamme P, Goossens G, Maleux G, Collen D, Stas M.

J Thromb Thrombolysis. 2007 Aug;24(1):1-5. Epub 2007 Feb 3.

PMID:
17278000
21.

Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae.

Snoeys J, Lievens J, Wisse E, Jacobs F, Duimel H, Collen D, Frederik P, De Geest B.

Gene Ther. 2007 Apr;14(7):604-12. Epub 2007 Jan 18.

PMID:
17235290
22.

Tiplaxtinin impairs nutritionally induced obesity in mice.

Lijnen HR, Alessi MC, Frederix L, Collen D, Juhan-Vague I.

Thromb Haemost. 2006 Dec;96(6):731-7.

PMID:
17139366
23.

Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development.

Voros G, Sandy JD, Collen D, Lijnen HR.

Biochim Biophys Acta. 2006 Dec;1760(12):1837-44. Epub 2006 Aug 26.

PMID:
17011710
24.

Impaired adipose tissue development in mice with inactivation of placental growth factor function.

Lijnen HR, Christiaens V, Scroyen I, Voros G, Tjwa M, Carmeliet P, Collen D.

Diabetes. 2006 Oct;55(10):2698-704.

25.

Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.

Vandendriessche T, Thorrez L, Acosta-Sanchez A, Petrus I, Wang L, Ma L, DE Waele L, Iwasaki Y, Gillijns V, Wilson JM, Collen D, Chuah MK.

J Thromb Haemost. 2007 Jan;5(1):16-24. Epub 2006 Sep 26.

26.

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.

Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR, Conway EM.

J Thromb Haemost. 2006 Aug;4(8):1813-24.

27.

Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants.

Thorrez L, Vandenburgh H, Callewaert N, Mertens N, Shansky J, Wang L, Arnout J, Collen D, Chuah M, Vandendriessche T.

Mol Ther. 2006 Sep;14(3):442-51. Epub 2006 Jun 5.

28.

Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.

Demeulemeester D, Scroyen I, Voros G, Snoeys J, De Geest B, Collen D, Lijnen HR.

Thromb Haemost. 2006 Jun;95(6):1019-24.

PMID:
16732382
29.

Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.

Jacquemin M, Radcliffe CM, Lavend'homme R, Wormald MR, Vanderelst L, Wallays G, Dewaele J, Collen D, Vermylen J, Dwek RA, Saint-Remy JM, Rudd PM, Dewerchin M.

J Thromb Haemost. 2006 May;4(5):1047-55.

30.

Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-1.

Semeraro F, Voros G, Collen D, Lijnen HR.

Thromb Haemost. 2006 Jan;95(1):174-81.

PMID:
16543977
31.

Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.

Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim IH, Szelid Z, Vermeersch P, Gillijns H, Pellens M, Grimminger F, van Zonneveld AJ, Collen D, Busse R, Janssens S.

Hypertension. 2006 Apr;47(4):762-70. Epub 2006 Feb 27.

32.

Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T.

Blood. 2006 Jun 15;107(12):4728-36. Epub 2006 Feb 14.

33.

Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.

Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Anglès-Cano E, Lijnen HR.

J Thromb Haemost. 2006 Mar;4(3):664-70.

34.

Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.

De Geest B, Snoeys J, Van Linthout S, Lievens J, Collen D.

Hum Gene Ther. 2005 Dec;16(12):1439-51.

PMID:
16390275
35.

Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.

Van Damme A, Thorrez L, Ma L, Vandenburgh H, Eyckmans J, Dell'Accio F, De Bari C, Luyten F, Lillicrap D, Collen D, VandenDriessche T, Chuah MK.

Stem Cells. 2006 Apr;24(4):896-907. Epub 2005 Dec 9.

36.

A genetic Xenopus laevis tadpole model to study lymphangiogenesis.

Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, Héligon C, Terclavers S, Ciesiolka M, Kälin R, Man WY, Senn I, Wyns S, Lupu F, Brändli A, Vleminckx K, Collen D, Dewerchin M, Conway EM, Moons L, Jain RK, Carmeliet P.

Nat Med. 2005 Sep;11(9):998-1004. Epub 2005 Aug 14.

PMID:
16116431
37.

Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.

Snoeys J, Mertens G, Lievens J, van Berkel T, Collen D, Biessen EA, De Geest B.

Mol Ther. 2006 Jan;13(1):98-107. Epub 2005 Aug 19.

38.

Genetic evidence for a tumor suppressor role of HIF-2alpha.

Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchin M, Jain RK, Plate KH, Carmeliet P.

Cancer Cell. 2005 Aug;8(2):131-41.

39.

Modulation of angiogenesis during adipose tissue development in murine models of obesity.

Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR.

Endocrinology. 2005 Oct;146(10):4545-54. Epub 2005 Jul 14.

40.
41.

Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain.

Melis E, Moons L, Arnout J, Hoylaerts MF, Collen D, Carmeliet P, Dewerchin M.

Biochem Biophys Res Commun. 2005 Jul 29;333(2):488-95.

PMID:
15961065
42.

On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.

Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I.

J Thromb Haemost. 2005 Jun;3(6):1174-9.

43.

Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study.

Lambrechts D, Devriendt K, Driscoll DA, Goldmuntz E, Gewillig M, Vlietinck R, Collen D, Carmeliet P.

J Med Genet. 2005 Jun;42(6):519-22. No abstract available.

44.

Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation.

Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC.

Circulation. 2005 May 31;111(21):2828-36. Epub 2005 May 23.

PMID:
15911697
45.

Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy.

Rossenbacker T, Schollen E, Kuipéri C, de Ravel TJ, Devriendt K, Matthijs G, Collen D, Heidbüchel H, Carmeliet P.

J Med Genet. 2005 May;42(5):e29.

46.

Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma.

Collen D, Hoylaerts MF.

J Am Coll Cardiol. 2005 May 3;45(9):1472-3. No abstract available.

47.

Thrombolytic agents.

Collen D, Lijnen HR.

Thromb Haemost. 2005 Apr;93(4):627-30. Review.

PMID:
15841305
48.

Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice.

Maquoi E, Vörös G, Carmeliet P, Collen D, Lijnen HR.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1002-7. Epub 2005 Feb 24.

PMID:
15731491
49.

Effect of matrix metalloproteinase inhibition on adipose tissue development.

Demeulemeester D, Collen D, Lijnen HR.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):105-10.

PMID:
15721280
50.

Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.

Rossenbacker T, Mubagwa K, Jongbloed RJ, Vereecke J, Devriendt K, Gewillig M, Carmeliet E, Collen D, Heidbüchel H, Carmeliet P.

Circulation. 2005 Mar 1;111(8):961-8. Epub 2005 Feb 7.

PMID:
15699249

Supplemental Content

Loading ...
Support Center